相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
Carol Moreno et al.
HAEMATOLOGICA (2022)
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
John F. Seymour et al.
BLOOD (2022)
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
Constantine S. Tam et al.
BLOOD (2022)
Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial
Tait D. Shanafelt et al.
BLOOD (2022)
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Constantine S. Tam et al.
LANCET ONCOLOGY (2022)
Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy
Jennifer A. Woyach et al.
BLOOD (2021)
First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr plus Ven) Versus Chlorambucil Plus Obinutuzumab (Clb plus O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study
Tahla Munir et al.
BLOOD (2021)
Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial
Alessandra Tedeschi et al.
BLOOD (2021)
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R Mato et al.
LANCET (2021)
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Alessandra Tedeschi et al.
BLOOD ADVANCES (2021)
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger et al.
LEUKEMIA (2020)
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Paolo Ghia et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Othman Al-Sawaf et al.
LANCET ONCOLOGY (2020)
Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)
Arnon P. Kater et al.
BLOOD (2020)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
K. Fischer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies
Philip A. Thompson et al.
LEUKEMIA (2018)
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation
J. Malcikova et al.
LEUKEMIA (2018)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations
R. Rosenquist et al.
LEUKEMIA (2017)
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
A. C. Rawstron et al.
LEUKEMIA (2016)
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
Mary Ann Anderson et al.
BLOOD (2016)
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
Barbara Eichhorst et al.
LANCET ONCOLOGY (2016)
Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR
Sara Raponi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Age at Diagnosis and the Utility of Prognostic Testing in Patients With Chronic Lymphocytic Leukemia
Tait D. Shanafelt et al.
CANCER (2010)
A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients
Fabio Salvi et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2008)
CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells
Rajendra N. Damle et al.
BLOOD (2007)
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia
S Ibrahim et al.
BLOOD (2001)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
